Evaluation of the Nutritional Supplement Lycoderm on Its Impact on Skin Parameters
NCT ID: NCT03402373
Last Updated: 2019-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2017-11-17
2019-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of 12-Week Dietary Intake of Lutein on Minimal Erythema Dose and Other Skin Parameters
NCT03811977
The Effects of LycoRed Phytonutrient and Vitamin Supplement (a.k.a. LYC-001e) on Ocular Blood Flow
NCT03068377
Effects of Isoflavone Combined With Astaxanthin on Skin Aging
NCT02373111
Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study
NCT06965426
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
NCT01048476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this study is to examine the effects of an oral antioxidant supplement on skin aging and skin condition.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lycoderm
soft gel contains nutritional supplement
Lycoderm
soft gel contains nutritional supplement
Placebo
Soft gel without active ingredients
Placebo
soft gel without active ingredients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lycoderm
soft gel contains nutritional supplement
Placebo
soft gel without active ingredients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects in good general health with no serious illnesses which might interfere with study participation per assessment of investigator.
3. Subjects with BMI \<30 kg/m2
4. Nonsmokers (self-reported)
5. Agree to maintain current dietary regimen
6. Agree to maintain current cosmetic regimen
7. Skin Type II/ III.
8. Subjects with dull skin, lack of radiance, uneven skin tone, lines and wrinkles as determined by an expert grader at Baseline.
Exclusion Criteria
2. Subjects that are not willing to to maintain current dietary regimen
3. Subjects that underwent extensive sunbathing in the month before study initiation or who plan to have excessive sun exposure or use a tanning bed/booth during the study.
4. Subjects that underwent procedures using injectables such as Botox or other fillers in 2 months before screening or who plan to undergo such procedures during the study.
5. Subjects with drastic change in body weight (greater than 10% 1 month prior to screening or during the study
6. Intake of vitamin or dietary supplements (especially Vitamin D3, carotenoids) during the month prior to screening
7. History of malabsorption diseases, liver diseases, or diseases of lipid metabolism.
8. History of photosensitizing disorders.
9. Use of medications which interact with the study procedures according to the principal investigator (during or prior to the study).
10. Subjects currently participating in a study or who have participated in any other clinical studies during the last 3 months prior to the study
11. Subjects having an acute or chronic disease or medical condition, including dermatological problems, which could put her at risk in the opinion of the Principal Investigator or compromise study outcomes.
12. History of allergic reactions, skin sensitization and/or known allergies to cosmetic ingredients, toiletries, sunscreens, etc.
13. Immunocompromised subjects .
14. Woman who started Hormone Replacement Therapy within the last three months preceding the screening visit.
15. Woman using oral contraception for less than three months before the screening visit or who has changed her contraceptive method within the three months before the Baseline visit or planning to modify her contraception treatment within the duration of the study.
17\. Woman known to be pregnant, lactating or planning to become pregnant within six months. Subjects who become pregnant during the study must inform the Principal Investigator immediately and will be excluded from the study.
\-
35 Years
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LycoRed Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Frumento, Phd
Role: STUDY_DIRECTOR
IRSI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
International Research Services, Inc.
Port Chester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4158LY0817
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.